Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma

Suramin is an antitrypanosomal agent with antineoplastic activity, but with serious systemic side effects. We administered Suramin intravesically to determine a concentration with low toxicity but with evidence of a pharmacodynamic effect, to recommend a dose level for phase II trials. This was an o...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Ord, J J, Streeter, E, Jones, A, Le Monnier, K, Cranston, D, Crew, J, Joel, S P, Rogers, M A, Banks, R E, Roberts, I S D, Harris, A L
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2005
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361814/
https://ncbi.nlm.nih.gov/pubmed/15928663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602650
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki